PFE vs ABBV
PFE and ABBV side by side — valuation & fundamentals (public data).
Key statistics
| Metric | PFEPfizer Inc. | ABBVAbbVie Inc. |
|---|---|---|
| Market cap | $143.48B | $470.72B |
| P/E (TTM) | 19.2 | 131.2 |
| P/B | 1.59 | — |
| P/S | 2.3x | 7.6x |
| Dividend yield | 6.81% | 2.48% |
| Revenue | $63.31B(TTM) | $61.16B(TTM) |
| Revenue growth (YoY) | -1.6% | 8.6% |
| Net income | $7.49B(TTM) | $3.63B(TTM) |
| Earnings growth (YoY) | -3.2% | -1.2% |
| EPS, diluted | $1.31(TTM) | $2.03(TTM) |
| EBIT margin | 16.3% | 24.6% |
| ROE | 8.6% | — |
| ROIC | 6.7% | 20.0% |
| 1y total return | +11.0% | +41.0% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: PFE vs ABBV
| 지표 | PFE | ABBV |
|---|---|---|
| 최종 가치 | $13.6K | $72.9K |
| 총수익률 | +35.5% | +628.8% |
| CAGR | +3.0% | +21.2% |
| 변동성 | 23.9% | 25.8% |
| 샤프 | 0.08 | 0.73 |
| 소르티노 | 0.11 | 1.01 |
| 최대 낙폭 | -59.0% | -45.1% |
공통 거래일 2600일 기준, 2016-03-28 → 2026-07-29 · 무위험수익률 3.9% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)